Minocycline In Neurocognitive Outcomes - Sickle Cell Disease

NCT05605366 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease
Cognitive Impairment
Cognitive Decline
Cognitive Change
Cognitive Dysfunction
Cognitive Deficit
Neuroinflammatory Response

Interventions

DRUG: Minocycline
DRUG: Placebo

Sponsor

University of Cincinnati